AKT1 and glioblastoma: Previous studies have shown that vitexin suppresses the growth of esophageal, liver, lung, colorectal, and ovarian cancers [12, 13], and vitexin was found to inhibit the cell viability in a dose- and time-dependent manner and induce G2/M cell cycle arrest and apoptosis by inhibiting Akt/mTOR signaling in human glioblastoma LN-18 cells, suggesting that vitexin may serve as a therapeutic agent for treatment of malignant glioblastoma [14].